Clinical Trial Resource
Welcome to the ACAAI Clinical Trial Resource page which connects physicians to existing clinical trials in allergy, asthma and immunology led by our pharmaceutical partners. Involvement in clinical trials provides the opportunity to further medical research and improve patient outcomes. While the ACAAI does not endorse these trials; we do encourage clinicians and their patients to partake in this valuable resource. Without these clinical trials, medical advancements would be greatly hindered.
To obtain information on how to become involved in a clinical trial, please browse the trial opportunities below.
The following trials listed are from the ACAAI 2017 Corporate Council Benefactor Members. If you are not a participating member, but would like to list your trial, please contact Linda Cullison at firstname.lastname@example.org.
Description: A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation (SOLANA)
Eligible Patient: Female and male aged 18 to 75 years inclusively at the time of Visit 1; Documented current treatment with ICS and LABA for at least 30 days prior to Visit 1. The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily. Additional asthma controller medications, eg, oral corticosteroids, long-acting antimuscarinics (LAMAs), LTRAs, theophylline etc. are allowed if they have been used for at least 30 days prior to Visit ; History of at least 2 asthma exacerbations that required treatment with systemic corticosteroids (intramuscular (IM), intravenous (IV), or oral) in the 12 months prior to Visit 1. For patients receiving corticosteroids as a maintenance therapy, the corticosteroid treatment for the exacerbation is defined as a temporary increase of their maintenance dose; Pre-bronchodilator (pre-BD) FEV1 of < 80% predicted at Visit 2 or Visit 3; Evidence of asthma as documented by airway reversibility (FEV1 ≥12% and 200 ml) demonstrated at Visit 1, Visit 2 or Visit 3. Peripheral blood eosinophil count of ≥300 cells/μL assessed by central lab at Visit.
Date Posted: August 16, 2016